The JAK-STAT pathway is involved in the pathogenesis of both the inflammatory bowel disease (IBD) and spondyloarthropathy group of diseases. The purpose of this study was to evaluate the effectiveness of tofacitinib, a Janus kinase inhibitor, in the treatment of enteropathic arthritis (EA). The study included seven patients, four from the authors' follow-up and three from the literature. All cases were recorded for demographic characteristics, comorbidities, IBD and EA symptoms, medical treatments and changes in clinical and laboratory results with treatment. Clinical and laboratory remission in terms of IBD and EA was achieved in three patients after tofacitinib treatment. For both spondyloarthritis spectrum diseases and IBD, tofacitinib may be an appropriate choice, as its efficacy has been shown in both conditions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2022-0110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Actual Insight into the Pathogenic Pathways of Ankylosing Spondylitis.
Curr Issues Mol Biol
November 2024
Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Article Synopsis
- * These conditions share common features like the absence of autoantibodies and genetic links, along with symptoms affecting joints and other body areas, but their exact causes are still not fully understood.
- * The article reviews current knowledge about the mechanisms behind ankylosing spondylitis, including genetic factors, environmental triggers, and immune responses that lead to inflammation and joint issues.
Article Synopsis
- - Axial spondyloarthritis, or ankylosing spondylitis, is a chronic inflammatory condition primarily affecting the spine but can also involve peripheral joints, and it is one of several disorders classified as spondyloarthropathies.
- - The condition is linked to specific genetic markers, particularly the HLA-B27 gene, and involves various inflammatory factors like tumor necrosis factor (TNF), along with the influence of non-HLA genes.
- - Recent studies suggest that gut microbiota and dysbiosis may contribute to the development of axial spondyloarthritis, highlighting the potential for future research into gut health in the context of this disease.
Prevalence of spondyloarthritis in inflammatory bowel disease according ASAS and ultrassonography and its correlation with plasma calprotectin.
Adv Rheumatol
April 2024
Rheumatology Department, University Hospital of the Federal University of Espírito Santo (Hucam-Ufes/Ebserh), Vitoria, Espírito Santo, Brazil.
Article Synopsis
- - The study focused on the prevalence of enteropathic spondyloarthritis (SpA) in patients with inflammatory bowel disease (IBD), finding that 13.5% met the Assessment of SpondyloArthritis International Society (ASAS) criteria, which increased to 22.8% when including ultrasonography (US) results.
- - A significant number of participants exhibited inflammatory musculoskeletal symptoms, with 42.1% having a high MASEI score, and US revealing 35% with synovitis and 14.7% with tenosynovitis.
- - Plasma calprotectin levels were similar to healthy individuals and only correlated with fecal calprotectin levels,
Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review.
Rheumatol Int
October 2024
Department of Rheumatology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that is associated with systemic inflammatory conditions. Currently, there is no universally accepted standard therapy for PG, but immunosuppressive (IS) treatment seems essential. We report a patient here who was successfully treated with tofacitinib despite being PG-refractory to multiple anti-tumor necrosis factor alpha (anti-TNF) therapies and conventional IS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!